Gene · 7068
Papers3,032
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
121 to 140 of 3,032
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
A multipart phase 1 study of the safety, pharmacodynamics and pharmacokinetics of ALG-055009, a novel thyroid hormone receptor beta (THR-β) agonist for metabolic dysfunction-associated steatohepatitis (MASH), in healthy participants. | Clin Pharmacol Drug Dev | 2026 | 40971152 | PubTator, text mining | PubMed |
| Efficacy and Safety of HSK31679 in Asian Patients With MASLD: A Randomized Controlled Trial. | Clin Gastroenterol Hepatol | 2026 | 40846146 | PubTator, text mining | PubMed |
| Incretin-based Agents and Metabolic Dysfunction-associated Steatotic Liver Disease. | Curr Pharm Des | 2026 | 40641020 | PubTator, text mining | PubMed |
| The Clinical and Genetic Diversity of Thyroid Hormone Resistance: Four Clinical Vignettes. | Horm Res Paediatr | 2026 | 39476806 | PubTator, text mining | PubMed |
| Nuclear Receptor-Targeted Therapy for Metabolic Dysfunction-Associated Steatotic Liver Disease. | Int J Drug Discov Pharm | 2025 | 41938103 | PubTator, text mining | PubMed |
| MASH and the race for liver antifibrotics. | Front Gastroenterol (Lausanne) | 2025 | 41822287 | PubTator, text mining | PubMed |
| Endocrine regulation of circadian rhythms. | NPJ Biol Timing Sleep | 2025 | 41775850 | PubTator, text mining | PubMed |
| Whole-Exome Sequencing in Recurrent Pregnancy Loss: Current Evidence and Future Directions in Saudi Arabia. | Med Arch | 2025 | 41768206 | PubTator, text mining | PubMed |
| Pre-treatment endocrine-nutritional signatures predict clinical benefit from PD-1/PD-L1 blockade in hematologic malignancies. | Front Nutr | 2025 | 41726000 | PubTator, text mining | PubMed |
| Efficacy of empagliflozin in patients with metabolic dysfunction-associated steatotic liver disease with or without diabetes: a systematic review and meta-analysis of randomized controlled trials. | Front Med (Lausanne) | 2025 | 41717349 | PubTator, text mining | PubMed |
| Synergistic therapeutic strategies for metabolic dysfunction-associated steatohepatitis and type 2 diabetes mellitus: molecular insights and clinical advances. | Front Endocrinol (Lausanne) | 2025 | 41635536 | PubTator, text mining | PubMed |
| Therapeutic Strategies for MASH: An Update on Drug Candidates Under Investigation in Late-Phase Clinical Trials. | Int J Transl Med (Basel) | 2025 | 41586160 | PubTator, text mining | PubMed |
| Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): New Perspectives on an Evolving Epidemic. | J Clin Med | 2025 | 41464774 | PubTator, text mining | PubMed |
| Thyroid hormone receptor beta (THRβ) Agonists in Metabolic Dysfunction-Associated Steatohepatitis (MASH): Bridging the Gap Between Promise and Practice. | J Gastrointestin Liver Dis | 2025 | 41453099 | PubTator, text mining | PubMed |
| Uncovering the genetic architecture of ME/CFS: a precision approach reveals impact of rare monogenic variation. | J Transl Med | 2025 | 41444612 | PubTator, text mining | PubMed |
| Research advances in the diagnosis and treatment of MASLD/MASH. | Ann Med | 2025 | 41421798 | PubTator, text mining | PubMed |
| Quick glance at 'metabolic dysfunction associated steatotic liver disease' therapeutics: Targets, trials, and trends. | World J Gastrointest Pharmacol Ther | 2025 | 41378068 | PubTator, text mining | PubMed |
| Application and Prospects of Large Language Models in Small-Molecule Drug Discovery. | Anal Chem | 2025 | 41366732 | PubTator, text mining | PubMed |
| Position Statement on Cardiometabolic Health Across the Woman's Life Course - 2025. | Rev Bras Ginecol Obstet | 2025 | 41346429 | PubTator, text mining | PubMed |
| Targeting THR-β for MASLD: Mechanisms and Drug Development. | Drug Des Devel Ther | 2025 | 41321669 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/7068/papers?page=7